We are live on ! Find out more
RPTX

Repare Therapeutics

Delisted

RPTX was delisted on the 27th of January, 2026.

71 hedge funds and large institutions have $167M invested in Repare Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

383% more call options, than puts

Call options by funds: $145K | Put options by funds: $30K

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

3% more funds holding

Funds holding: 6971 (+2)

3.28% less ownership

Funds ownership: 87.47%84.19% (-3.3%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

36% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 25

38% less capital invested

Capital invested by funds: $269M → $167M (-$102M)

Holders
71
Holders Change
+2
Holders Change %
+2.9%
% of All Funds
1.02%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
6
Increased
16
Reduced
25
Closed
4
Calls
$145K
Puts
$30K
Net Calls
+$115K
Net Calls Change
-$172K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$48.7M
O
2
OrbiMed
New York
$15.6M
BOCH
3
Blue Owl Capital Holdings
New York
$14.7M
AIM
4
ARK Investment Management
Florida
$12.7M -$755K -117,777 -4%
DTC
5
Deep Track Capital
Connecticut
$12.6M -$1.98M -308,387 -10%
VVM
6
Versant Venture Management
California
$12.5M
MAM
7
MPM Asset Management
Massachusetts
$10.6M
RG
8
Redmile Group
California
$9.5M -$849K -132,446 -6%
MB
9
MPM BioImpact
Massachusetts
$7.72M
AG
10
Artal Group
Luxembourg
$3.3M
ACM
11
Aquilo Capital Management
California
$2.98M
Renaissance Technologies
12
Renaissance Technologies
New York
$1.65M -$30.9K -4,826 -1%
Ensign Peak Advisors
13
Ensign Peak Advisors
Utah
$1.62M
Sumitomo Mitsui Trust Group
14
Sumitomo Mitsui Trust Group
Japan
$1.45M -$113K -17,562 -5%
NAMA
15
Nikko Asset Management Americas
New York
$1.43M -$113K -17,562 -5%
Morgan Stanley
16
Morgan Stanley
New York
$1.35M -$2.43M -378,989 -57%
Millennium Management
17
Millennium Management
New York
$795K -$84.8K -13,232 -7%
HS
18
HighVista Strategies
Massachusetts
$778K
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$625K +$299K +46,648 +53%
GCP
20
GSA Capital Partners
United Kingdom
$594K -$117K -18,242 -13%
D.E. Shaw & Co
21
D.E. Shaw & Co
New York
$566K +$275K +42,954 +56%
Bank of Montreal
22
Bank of Montreal
Ontario, Canada
$509K +$1.92K +300 +0.3%
OM
23
Opaleye Management
Massachusetts
$318K +$433K +67,561 New
Two Sigma Investments
24
Two Sigma Investments
New York
$314K +$264K +41,277 +162%
Citadel Advisors
25
Citadel Advisors
Florida
$314K +$128K +19,945 +43%

RPTX Hedge Fund Activity: Q1 2024 in Review

71 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q1 2024, worth a combined $167M — down 38% from $269M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new RPTX positions and 4 closed out — a net gain of 2 holders — while 16 added to existing stakes and 25 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $433K. The largest seller was Logos Global Management, exiting entirely with an estimated $4.38M sold.

  • 71 institutional investors held Repare Therapeutics (RPTX) as of Q1 2024, up from 69 in Q4 2023.
  • Funds reported $167M of Repare Therapeutics stock for Q1 2024, down 38% quarter-over-quarter.
  • 6 funds opened new Repare Therapeutics positions in Q1 2024 and 4 closed out, a net change of +2 holders.
  • The largest Repare Therapeutics buyer in Q1 2024 was Opaleye Management, an estimated $433K added.
  • The largest Repare Therapeutics seller in Q1 2024 was Logos Global Management, an estimated $4.38M sold.

Based on aggregated 13F filings for Q1 2024.